Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins

被引:10
|
作者
Khattar, Sunil K. [1 ]
DeVico, Anthony L. [2 ]
LaBranche, Celia C. [3 ]
Panda, Aruna [4 ,5 ,6 ]
Montefiori, David C. [3 ]
Samal, Siba K. [1 ]
机构
[1] Univ Maryland, Virginia Maryland Reg Coll Vet Med, College Pk, MD 20742 USA
[2] Univ Maryland, Sch Med, Inst Human Virol, Div Basic Sci, Baltimore, MD 21201 USA
[3] Duke Univ, Div Surg Sci, Durham, NC USA
[4] Univ Maryland, Sch Med, Dept Pathol, Program Comparat Med, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Epidemiol, Program Comparat Med, Baltimore, MD 21201 USA
[6] Univ Maryland, Sch Med, Dept Publ Hlth, Program Comparat Med, Baltimore, MD 21201 USA
关键词
NEUTRALIZING ANTIBODIES; VECTORED VACCINE; GLYCOPROTEIN; IMMUNIZATION; IMMUNOGENICITY; ELICITATION; MACAQUES; PRIMATES; SUBTYPE; MUCOSAL;
D O I
10.1128/JVI.02847-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Newcastle disease virus (NDV) expressing HIV-1 BaL gp160 was evaluated either alone or with monomeric BaL gp120 and BaL SOSIP gp140 protein in a prime-boost combination in guinea pigs to enhance envelope (Env)-specific humoral and mucosal immune responses. We showed that a regimen consisting of an NDV prime followed by a protein boost elicited stronger serum and mucosal Th-1-biased IgG responses and neutralizing antibody responses than NDV-only immunizations. Additionally, these responses were higher after the gp120 than after the SOSIP gp140 protein boost.
引用
收藏
页码:1682 / 1686
页数:5
相关论文
共 50 条
  • [31] Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
    Kong, Leopold
    Lee, Jeong Hyun
    Doores, Katie J.
    Murin, Charles D.
    Julien, Jean-Philippe
    McBride, Ryan
    Liu, Yan
    Marozsan, Andre
    Cupo, Albert
    Klasse, Per-Johan
    Hoffenberg, Simon
    Caulfield, Michael
    King, C. Richter
    Hua, Yuanzi
    Le, Khoa M.
    Khayat, Reza
    Deller, Marc C.
    Clayton, Thomas
    Tien, Henry
    Feizi, Ten
    Sanders, Rogier W.
    Paulson, James C.
    Moore, John P.
    Stanfield, Robyn L.
    Burton, Dennis R.
    Ward, Andrew B.
    Wilson, Ian A.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2013, 20 (07) : 796 - +
  • [32] Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses
    Megati, Shakuntala
    Garcia-Hand, Dorys
    Cappello, Sarah
    Roopchand, Vidia
    Masood, Amjed
    Xu, Rong
    Luckay, Amara
    Chong, Siew-Yen
    Rosati, Margherita
    Sackitey, Solomon
    Weiner, David B.
    Felber, Barbara K.
    Pavlakis, George N.
    Israel, Zimra R.
    Smith, Larry R.
    Eldridge, John H.
    Sidhu, Maninder K.
    Egan, Michael A.
    VACCINE, 2008, 26 (40) : 5083 - 5094
  • [33] CHARACTERIZATION OF RECOMBINANT GP120 AND GP160 FROM HIV-1 - BINDING TO MONOCLONAL-ANTIBODIES AND SOLUBLE CD4
    MOORE, JP
    MCKEATING, JA
    JONES, IM
    STEPHENS, PE
    CLEMENTS, G
    THOMSON, S
    WEISS, RA
    AIDS, 1990, 4 (04) : 307 - 315
  • [34] MONOCLONAL-ANTIBODIES TO GP160 OF HIV-1 THAT NEUTRALIZE HIV-1 INFECTIVITY, BLOCK THE BINDING OF GP120 TO CD4, AND REACT WITH DIVERSE ISOLATES
    BERMAN, PW
    ROSENTHAL, K
    NAKAMURA, G
    RIDDLE, L
    PORTER, JP
    DOWBENKO, D
    HOBBES, M
    BYRN, R
    GROOPMAN, J
    GREGORY, T
    FENDLY, B
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1991, 4 (03): : 306 - 306
  • [35] In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120
    Visciano, Maria Luisa
    Tuen, Michael
    Gorny, Miroslaw K.
    Hioe, Catarina E.
    VIROLOGY, 2008, 372 (02) : 409 - 420
  • [36] LYMPHOPROLIFERATIVE RESPONSES TO A CANDIDATE HIV-1 GP120 SUBUNIT VACCINE IN HUMAN VOLUNTEERS
    BAENZIGER, J
    SINANGIL, F
    REECE, J
    SAKAMOTO, D
    RODDA, S
    KAHN, J
    CHERNOFF, D
    DEKKER, C
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 78 - 78
  • [37] Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine
    Lambert, JS
    Viscidi, R
    Walker, MC
    Clayman, B
    Winget, M
    Wolff, M
    Schwartz, DH
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (03) : 302 - 308
  • [38] THE CONVERTASES FURIN AND PC1 CAN BOTH CLEAVE THE HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 ENVELOPE GLYCOPROTEIN GP160 INTO GP120 (HIV-I SU) AND GP41 (HIV-I TM)
    DECROLY, E
    VANDENBRANDEN, M
    RUYSSCHAERT, JM
    COGNIAUX, J
    JACOB, GS
    HOWARD, SC
    MARSHALL, G
    KOMPELLI, A
    BASAK, A
    JEAN, F
    LAZURE, C
    BENJANNET, S
    CHRETIEN, M
    DAY, R
    SEIDAH, NG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (16) : 12240 - 12247
  • [39] Priming with a Mixture of Recombinant BCG Expressing HIV-1 Gag, RT and gp120 and Boosting with Recombinant MVA Induces an Effective Immune Response
    Chapman, R. E.
    Shephard, E.
    Stutz, H.
    Chege, G.
    Douglass, N.
    Williamson, A.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A99 - A99
  • [40] Immune responses to an HIV-1 gp140 Envelope DNA vaccine are synergistically enhanced by IL-12 combined with Tumor Necrosis Factor superfamily (TNFSF)
    Kanagavelu, S.
    Rivas, Y.
    Gupta, S.
    Termini, J.
    Kornbluth, R. S.
    Stone, G. W.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (10) : A40 - A40